{"product_id":"jcrpharm-swot-analysis","title":"JCR Pharmaceuticals SWOT Analysis","description":"\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eAnalyzes JCR Pharmaceuticals’s competitive position through key internal and external factors.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eSimplifies strategy, summarizing insights into the JCR Pharmaceuticals' SWOT position.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eJCR Pharmaceuticals SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eYou're seeing a direct snapshot of the JCR Pharmaceuticals SWOT analysis document. \u003c\/p\u003e\n\u003cp\u003eThis preview accurately represents the structure, content, and detail of the final report. \u003c\/p\u003e\n\u003cp\u003ePurchasing the analysis grants immediate access to the full, comprehensive document. \u003c\/p\u003e\n\u003cp\u003eIt's the same quality and format you see here—no hidden sections.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003ch2\u003eSWOT Analysis Template\u003c\/h2\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMake Insightful Decisions Backed by Expert Research\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eOur glimpse into JCR Pharmaceuticals' SWOT reveals key areas like product innovation. We highlight opportunities in market expansion and rising regulatory demands. However, potential threats and internal weaknesses require deeper examination. This snippet only scratches the surface of a comprehensive strategic evaluation.\n\u003c\/p\u003e\n\u003cp\u003eDiscover the complete picture behind the company’s market position with our full SWOT analysis. This in-depth report reveals actionable insights, financial context, and strategic takeaways—ideal for entrepreneurs, analysts, and investors.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProprietary Technology in Rare Diseases\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eJCR Pharmaceuticals' J-Brain Cargo® tech is a strength. It enables delivery of biotherapeutics across the blood-brain barrier, crucial for treating neurological symptoms. This tech is vital for lysosomal storage disorders, a market estimated at $2.5B globally by 2024. This positions JCR favorably in a high-need area.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFocus on Rare and Genetic Diseases\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eJCR Pharmaceuticals excels in rare and genetic diseases, addressing significant unmet medical needs. This niche focus reduces competition, enabling premium pricing strategies. In 2024, the orphan drug market was valued at approximately $200 billion, reflecting the potential for high returns. JCR's specialization fosters a strong presence in these specialized markets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eApproved Products and Pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eJCR Pharmaceuticals boasts a robust portfolio of approved products in Japan. These products address conditions like growth disorders and Fabry disease. The company's pipeline includes investigational drugs for rare diseases, with global clinical trials underway. JCR's focus on rare diseases positions it well in a specialized market. In 2024, the orphan drug market is estimated at $200 billion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Expansion Efforts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eJCR Pharmaceuticals is strategically broadening its global presence. They are actively involved in clinical trials across the US, Europe, and Latin America. This international expansion is crucial for reaching a larger patient base and boosting revenue. For instance, in 2024, international sales accounted for 35% of JCR's total revenue, a 5% increase from the previous year.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eIncreased Market Reach:\u003c\/strong\u003e Expanding into new markets allows JCR to tap into previously inaccessible patient populations.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eRevenue Growth:\u003c\/strong\u003e International sales contribute significantly to JCR's overall financial performance.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eDiversification:\u003c\/strong\u003e Reduces reliance on any single market, mitigating risk.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eEnhanced Reputation:\u003c\/strong\u003e Global presence boosts the company's credibility and visibility.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCollaborations and Partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eJCR Pharmaceuticals benefits from strategic collaborations and partnerships. For example, the company partnered with Alexion, AstraZeneca Rare Disease, for research, which leverages its tech. These alliances grant access to crucial resources, expertise, and potential income. In 2024, such collaborations are projected to boost R\u0026amp;D revenue by 15%. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003eIncreased R\u0026amp;D efficiency through shared resources.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eAccess to a broader market reach via partner networks.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003ePotential for milestone payments and royalty income.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eEnhanced credibility and validation of JCR's technologies.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNeuro-Tech Powering Pharma's $200B+ Future\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eJCR Pharmaceuticals has a potent tech platform, J-Brain Cargo®, allowing biotherapeutic delivery across the blood-brain barrier; this platform is vital for neurological treatments, particularly in the $2.5B lysosomal storage disorder market by 2024.\u003c\/p\u003e\n\u003cp\u003eThe company excels in rare and genetic diseases, creating a competitive advantage and enabling premium pricing. The orphan drug market, estimated at $200 billion in 2024, indicates considerable growth potential.\u003c\/p\u003e\n\u003cp\u003eJCR Pharmaceuticals has a solid foundation of approved products and a robust pipeline. The focus is on global clinical trials, with international sales growing, representing 35% of the total revenue, up 5% from the previous year.\u003c\/p\u003e\n\u003cp\u003eJCR's strategic collaborations amplify efficiency and expand market reach. Collaborations are projected to increase R\u0026amp;D revenue by 15% in 2024.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eStrength\u003c\/th\u003e\n\u003cth\u003eDetails\u003c\/th\u003e\n\u003cth\u003eImpact\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eJ-Brain Cargo® Tech\u003c\/td\u003e\n\u003ctd\u003eDelivers biotherapeutics across the blood-brain barrier.\u003c\/td\u003e\n\u003ctd\u003eAddresses $2.5B market for lysosomal disorders.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFocus on Rare Diseases\u003c\/td\u003e\n\u003ctd\u003eNiche focus, reducing competition and driving premium pricing.\u003c\/td\u003e\n\u003ctd\u003eLeverages $200B orphan drug market potential.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eApproved Products \u0026amp; Pipeline\u003c\/td\u003e\n\u003ctd\u003ePortfolio of products with ongoing global trials.\u003c\/td\u003e\n\u003ctd\u003eInternational sales represent 35% of revenue.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStrategic Alliances\u003c\/td\u003e\n\u003ctd\u003eCollaborations driving resource access \u0026amp; income.\u003c\/td\u003e\n\u003ctd\u003e15% R\u0026amp;D revenue increase in 2024 from partnerships.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFinancial Performance Challenges\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eJCR Pharmaceuticals faces financial performance challenges. The company revised its consolidated earnings forecasts downward for the fiscal year ending March 31, 2025. They now anticipate a net loss due to a licensing agreement not finalizing. Increased costs from inventory write-offs and R\u0026amp;D expenses contribute to this financial strain. For example, R\u0026amp;D expenses might reach $50 million by early 2025.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReliance on Specific Technologies and Pipeline Success\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eJCR Pharmaceuticals faces risks tied to its technologies and product pipeline.\u003c\/p\u003e\n\u003cp\u003eSuccess depends on J-Brain Cargo® and pipeline approvals.\u003c\/p\u003e\n\u003cp\u003eDelays or failures in clinical trials and approvals could hurt JCR.\u003c\/p\u003e\n\u003cp\u003eFor instance, Phase 3 trial setbacks could significantly impact revenue projections, potentially affecting the stock price by 10-15% as seen in similar biotech companies during 2024-2025.\u003c\/p\u003e\n\u003cp\u003eRegulatory challenges and unfavorable results for key candidates are major concerns.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCompetition in Rare Disease Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eWhile JCR Pharmaceuticals targets rare diseases, competition exists. Companies like Takeda are developing treatments for Hunter syndrome. This competition may reduce market share. For instance, the rare disease market was valued at $215.8 billion in 2023.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing and Supply Chain Risks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eJCR Pharmaceuticals faces weaknesses in manufacturing and supply chain risks, which are common in the pharmaceutical industry, especially for rare disease treatments. Manufacturing issues and delays can directly impact product availability. A robust global supply chain is essential. These challenges can affect profitability. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003eIn 2024, the FDA reported an average of 1,200 drug shortages annually.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eSupply chain disruptions increased manufacturing costs by 15% in 2023.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eThe rare disease market is projected to reach $350 billion by 2027.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory and Pricing Pressures\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eJCR Pharmaceuticals faces weaknesses due to regulatory and pricing pressures within the pharmaceutical sector. Stringent regulations and market-specific pricing constraints can significantly impact JCR's financial performance. Any shifts in regulatory demands or policies designed to decrease drug expenses could adversely affect both revenue and profitability. These pressures necessitate careful strategic planning and adaptation. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003eIn 2024, the pharmaceutical industry saw a 6% decrease in drug prices due to regulatory actions.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eThe average time to market for a new drug is 10-12 years, increasing regulatory costs.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003ePricing pressures are particularly acute in Europe, where price controls are common.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eJCR Pharmaceuticals: Financial and Operational Hurdles\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eJCR Pharmaceuticals' weaknesses include financial underperformance, highlighted by lowered earnings forecasts for fiscal year 2025 and escalating R\u0026amp;D costs, potentially reaching $50 million. The firm depends heavily on the success of J-Brain Cargo® and pipeline approvals, with delays potentially affecting revenue by 10-15%. Regulatory challenges, pricing pressures, and supply chain risks further strain its profitability.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct orange_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eWeakness\u003c\/th\u003e\n\u003cth\u003eImpact\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancial Performance\u003c\/td\u003e\n\u003ctd\u003eNet Loss Anticipated\u003c\/td\u003e\n\u003ctd\u003eDownward revised earnings for FY2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePipeline Dependency\u003c\/td\u003e\n\u003ctd\u003eApproval Delays\u003c\/td\u003e\n\u003ctd\u003e10-15% potential revenue impact (Phase 3 setback)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory\/Pricing Pressures\u003c\/td\u003e\n\u003ctd\u003eReduced Profitability\u003c\/td\u003e\n\u003ctd\u003e6% decrease in drug prices (2024, regulatory)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"SAE","offers":[{"title":"Default Title","offer_id":56069495947648,"sku":"jcrpharm-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0899\/6510\/1440\/files\/jcrpharm-swot-analysis.png?v=1749390975","url":"https:\/\/swotanalysistemplates.com\/products\/jcrpharm-swot-analysis","provider":"SWOT Analysis Templates","version":"1.0","type":"link"}